Thrombosis in Myeloproliferative Neoplasms

Abstract

Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and it involves various abnormalities of platelets, erythrocytes, and leukocytes, as well as dysfunctions of endothelial cells. These include not only elevations in the counts of circulating blood cells, arising from the clonal proliferation of hematopoietic progenitor cells, but also modifications of several physiological/molecular properties. Patients with MPN can be stratified in “high-risk” or “low-risk” thrombotic categories according to the age and history of thrombosis. The most commonly used front-line drugs for the treatment of high-risk patients include hydroxyurea and interferon alpha, whereas in low-risk patients, primary antithrombotic prophylaxis with aspirin is used. Future research should be focused on the evaluation of the role of biomarkers in identifying MPN patients at higher risk of thrombosis, who may benefit from primary thromboprophylaxis. Finally, a better understanding of the molecular events leading to the progress of the hypercoagulable state in MPN patients may provide appropriate tools for the development of targeted therapies based on reversal of coagulopathy.

Keywords

myeloproliferative neoplasms - thrombosis - risk factors

• References

• 1 Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010; 91 (2) 174-179
• 2 Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88 (6) 507-516
• 3 Them NC, Kralovics R. Genetic basis of MPN: beyond JAK2-V617F. Curr Hematol Malig Rep 2013; 8 (4) 299-306
• 4 Cervantes F, Dupriez B, Pereira A , et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113 (13) 2895-2901
• 5 Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010; 102 (3) 83-87
• 6 Barbui T, Carobbio A, Cervantes F , et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115 (4) 778-782
• 7 Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 571-581
• 8 Marchetti M, Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb 2008; 36 (3-4) 148-159
• 9 Tefferi A. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86 (3) 292-301
• 10 Falanga A, Marchetti M, Evangelista V , et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96 (13) 4261-4266
• 11 Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC , et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009; 84 (2) 102-108
• 12 Reikvam H, Tiu RV. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera. Leukemia 2012; 26 (4) 563-571
• 13 Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013; 162 (6) 730-747
• 14 Kiladjian JJ, Cervantes F, Leebeek FW , et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111 (10) 4922-4929
• 15 Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012; 120 (25) 4921-4928
• 16 Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128 (3) 275-290
• 17 Marchioli R, Finazzi G, Landolfi R , et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23 (10) 2224-2232
• 18 Marchioli R, Finazzi G, Specchia G , et al; CYTO-PV Collaborative Group Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013; 368 (1) 22-33
• 19 Carobbio A, Thiele J, Passamonti F , et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
• 20 Harrison CN, Campbell PJ, Buck G , et al; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353 (1) 33-45
• 21 De Stefano V, Za T, Rossi E , et al; GIMEMA CMD-Working Party Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93 (3) 372-380
• 22 Barbui T, Barosi G, Birgegard G , et al; European LeukemiaNet Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29 (6) 761-770
• 23 Adams BD, Baker R, Lopez JA, Spencer S. Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am 2010; 24 (3) 585-602
• 24 Di Nisio M, Barbui T, Di Gennaro L , et al; European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136 (2) 249-259
• 25 Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?. Blood 2006; 108 (7) 2493-2494
• 26 Cortelazzo S, Finazzi G, Ruggeri M , et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332 (17) 1132-1136
• 27 Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006; 19 (3) 617-633
• 28 Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program) 2005; 409-415
• 29 Schafer AI. Thrombocytosis. N Engl J Med 2004; 350 (12) 1211-1219
• 30 Landolfi R, Di Gennaro L, Barbui T , et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109 (6) 2446-2452
• 31 Carobbio A, Antonioli E, Guglielmelli P , et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26 (16) 2732-2736
• 32 Carobbio A, Finazzi G, Guerini V , et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109 (6) 2310-2313
• 33 Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011; 90 (8) 933-938
• 34 Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81 (2) 159-166
• 35 Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009; 115 (24) 5740-5745
• 36 De Stefano V, Za T, Rossi E , et al; GIMEMA Chronic Myeloproliferative Neoplasms Working Party Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 2010; 85 (2) 97-100
• 37 Campbell PJ, MacLean C, Beer PA , et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood 2012; 120 (7) 1409-1411
• 38 Passamonti F, Rumi E, Pascutto C, Cazzola M, Lazzarino M. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009; 7 (9) 1587-1589
• 39 Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008; 93 (9) 1412-1414
• 40 Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33 (1) 67-73
• 41 Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR, Cattaneo M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009; 124 (4) 409-417
• 42 Lee HS, Park LC, Lee EM , et al. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea. Clin Lymphoma Myeloma Leuk 2012; 12 (1) 70-75
• 43 Carobbio A, Finazzi G, Antonioli E , et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 2009; 37 (9) 1016-1021
• 44 Passamonti F, Rumi E, Pietra D , et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010; 24 (9) 1574-1579
• 45 Ruggeri M, Gisslinger H, Tosetto A , et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002; 71 (1) 1-6
• 46 Gisslinger H, Müllner M, Pabinger I , et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica 2005; 90 (3) 408-410
• 47 Trifa AP, Cucuianu A, Popp RA , et al. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia. Ann Hematol 2014; 93 (2) 203-209
• 48 Amitrano L, Guardascione MA, Ames PR , et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003; 72 (2) 75-81
• 49 Kornblihtt LI, Heller PG, Correa G , et al. Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations. Thromb Res 2003; 112 (3) 131-135
• 50 Afshar-Kharghan V, López JA, Gray LA , et al. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 2004; 15 (1) 21-24
• 51 Barbui T, Finazzi G, Carobbio A , et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
• 52 Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Hematol 1995; 20 (3) 203-222
• 53 Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33 (5) 523-530
• 54 Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91 (2) 169-175
• 55 Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 2000; 110 (1) 116-124
• 56 Panova-Noeva M, Marchetti M, Spronk HM , et al. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 2011; 86 (4) 337-342
• 57 Panova-Noeva M, Marchetti M, Buoro S , et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 2011; 118 (9) 2599-2601
• 58 Hobbs CM, Manning H, Bennett C , et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. Blood 2013; 122 (23) 3787-3797
• 59 Landolfi R, Ciabattoni G, Patrignani P , et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80 (8) 1965-1971
• 60 Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science 1980; 207 (4430) 541-543
• 61 Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005; 42 (4) 239-247
• 62 Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13 (1) 34-39
• 63 Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T , et al. Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica 2013; 98 (10) 1517-1524
• 64 Friedenberg WR, Roberts RC, David DE. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol 1992; 40 (4) 283-289
• 65 Cella G, Marchetti M, Vianello F , et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 2010; 104 (1) 151-156
• 66 Falanga A, Marchetti M, Vignoli A , et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35 (5) 702-711
• 67 Karakantza M, Giannakoulas NC, Zikos P , et al. Markers of endothelial and in vivo platelet activation in patients with essential thrombocythemia and polycythemia vera. Int J Hematol 2004; 79 (3) 253-259
• 68 Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J Thromb Haemost 2003; 1 (6) 1183-1188
• 69 Di Raimondo F, Palumbo GA, Molica S, Giustolisi R. Angiogenesis in chronic myeloproliferative diseases. Acta Haematol 2001; 106 (4) 177-183
• 70 Treliński J, Wierzbowska A, Krawczyńska A , et al. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. Leuk Lymphoma 2010; 51 (9) 1727-1733
• 71 Belotti A, Elli E, Speranza T, Lanzi E, Pioltelli P, Pogliani E. Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment—flow cytometry and soluble E-selectin detection. Am J Hematol 2012; 87 (3) 319-320
• 72 Alonci A, Allegra A, Bellomo G , et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol 2008; 26 (4) 235-239
• 73 Kubota Y, Tanaka T, Ohnishi H , et al. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 2004; 18 (6) 1127-1137
• 74 Rafail S, Ritis K, Schaefer K , et al. Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNFalpha involvement. Thromb Res 2008; 122 (3) 366-375
• 75 Sozer S, Hoffman R. Laser-capture microdissection and analysis of liver endothelial cells from patients with Budd-Chiari syndrome. Methods Mol Biol 2011; 755: 405-415
• 76 Beer PA, Campbell PJ, Scott LM , et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112 (1) 141-149
• 77 Vannucchi AM, Antonioli E, Guglielmelli P , et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008; 112 (3) 844-847
• 78 Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52 (1) 14-20
• 79 Marchetti M, Castoldi E, Spronk HM , et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112 (10) 4061-4068
• 80 Brinkman HJ, Mertens K, van Mourik JA. Proteolytic cleavage of protein S during the hemostatic response. J Thromb Haemost 2005; 3 (12) 2712-2720
• 81 Dienava-Verdoold I, Marchetti MR, te Boome LC , et al. Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies. Thromb Haemost 2012; 107 (3) 468-476
• 82 Zwicker JI, Liebman HA, Neuberg D , et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15 (22) 6830-6840
• 83 Trappenburg MC, van Schilfgaarde M, Marchetti M , et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009; 94 (7) 911-918
• 84 Marchetti M, Tartari CJ, Russo L , et al. Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 2013;
• 85 Mignon I, Grand F, Boyer F, Hunault-Berger M, Hamel JF, Macchi L. Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis. Am J Hematol 2013; 88 (12) 1007-1011
• 86 Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 2010; 126 (3) 238-242
• 87 Landolfi R, Marchioli R, Kutti J , et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350 (2) 114-124
• 88 Alvarez-Larrán A, Cervantes F, Pereira A , et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116 (8) 1205-1210 , quiz 1387
• 89 Sterkers Y, Preudhomme C, Laï JL , et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91 (2) 616-622
• 90 Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110 (3) 577-583
• 91 Maugeri N, Giordano G, Petrilli MP , et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?. J Thromb Haemost 2006; 4 (12) 2593-2598
• 92 Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 2013; 6 (1) 49-58
• 93 Kiladjian JJ, Cassinat B, Chevret S , et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112 (8) 3065-3072
• 94 Quintás-Cardama A, Kantarjian H, Manshouri T , et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27 (32) 5418-5424
• 95 Samuelsson J, Mutschler M, Birgegård G, Gram-Hansen P, Björkholm M, Pahl HL. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 2006; 91 (9) 1281-1282
• 96 Ianotto JC, Boyer-Perrard F, Gyan E , et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013; 162 (6) 783-791
• 97 Gisslinger H, Gotic M, Holowiecki J , et al; ANAHYDRET Study Group Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013; 121 (10) 1720-1728